Biotech Veteran Sanjiv Lal Accelerates Regenerative Medicine Growth With Expanded Industry Collaborations

LOS ANGELES, CA, August 18, 2026 (EZ Newswire) -- Biotechnology entrepreneur and healthcare executive Sanjiv Lal, CEO and co-founder of Regen Therapy, is expanding industry collaborations designed to advance physician education, strengthen clinical partnerships, and support the responsible growth of regenerative medicine and longevity-focused healthcare.

The expanded collaborations reflect Regen Therapy's continued commitment to helping bridge the gap between emerging scientific research and everyday clinical practice through education, interdisciplinary partnerships, and evidence-informed healthcare initiatives.

Expanding Physician Education and Clinical Collaboration

Drawing on more than 24 years of experience across pharmaceuticals, biotechnology, molecular genetics, diagnostics, and laboratory operations, Sanjiv Lal has built a career focused on translating scientific innovation into practical healthcare solutions. Throughout his professional journey, Lal has founded and scaled multiple biotechnology laboratory organizations while working to improve access to education and operational resources for healthcare providers.

Through Regen Therapy, Lal is expanding physician education initiatives that include weekly webinars, live clinical training, educational resources, and collaborative programs focused on regenerative medicine, cellular signaling, and healthy aging. These initiatives are designed to help healthcare professionals better understand emerging therapies while supporting responsible clinical implementation.

"Regenerative medicine continues to advance rapidly, but education and clinical adoption must evolve alongside the science," said Lal. "Our goal is to provide physicians with practical, evidence-informed educational resources while fostering meaningful collaborations that support responsible innovation and improved patient care."

Supporting Responsible Growth in Regenerative Medicine

The expanded collaborations bring together healthcare providers, researchers, healthcare organizations, and industry leaders committed to advancing regenerative medicine through scientific integrity, education, and measurable clinical outcomes.

Rather than positioning regenerative medicine as an alternative to conventional healthcare, Regen Therapy promotes an integrated approach that combines traditional medicine, diagnostics, regenerative therapies, lifestyle strategies, and emerging technologies. The company's educational initiatives are intended to encourage interdisciplinary collaboration while helping establish stronger clinical standards as the field continues to mature.

According to Sanjiv Lal, building trust within regenerative medicine requires more than scientific advancement. It also requires consistent education, collaboration, and responsible implementation that enables healthcare professionals to confidently evaluate and integrate emerging innovations into patient care.

Expanding Industry Leadership and Strategic Partnerships

In addition to leading Regen Therapy, Sanjiv Lal remains actively involved in conferences, healthcare innovation summits, physician education events, and industry discussions focused on biotechnology, longevity science, and personalized healthcare.

Recent milestones include co-curating the Longevity Leadership Conference at the Verizon Innovation Lab in Los Angeles and supporting Regen Therapy's partnership with Hall of Fame Health to expand regenerative medicine and longevity resources for elite athletes and veterans. Sanjiv Lal also serves on the Nugevia™ Advisory Board for Jupiter Neurosciences (NASDAQ: JUNS), contributing industry expertise to initiatives focused on healthcare innovation.

These collaborations reflect Regen Therapy's broader mission to strengthen the educational and operational infrastructure that supports the continued evolution of regenerative medicine within modern healthcare.

Looking Ahead

As regenerative medicine continues to evolve, Sanjiv Lal believes healthcare is moving toward a future that places greater emphasis on preserving function, resilience, and long-term quality of life through earlier intervention and personalized care.

Looking ahead, Regen Therapy plans to continue expanding physician education programs, strengthening strategic partnerships, and supporting initiatives that improve access to regenerative medicine education for healthcare professionals nationwide. Through continued collaboration with clinicians, researchers, healthcare organizations, and industry innovators, the company aims to help advance responsible clinical adoption while fostering greater understanding of longevity science and regenerative medicine.

"Scientific breakthroughs create opportunity, but lasting impact comes from education, collaboration, and trust," said Lal. "By working together across disciplines, we can help build the clinical and educational foundation."

About Sanjiv Lal

Sanjiv Lal is the CEO and co-founder of Regen Therapy. With over 24 years of experience in pharmaceuticals, biotechnology, molecular genetics, diagnostics, and regenerative medicine, Sanjiv Lal has founded and scaled multiple biotechnology organizations while helping advance physician education, clinical collaboration, and healthcare innovation. Through Regen Therapy, he works to support the responsible integration of regenerative medicine into modern healthcare through education, scientific collaboration, and evidence-informed clinical practices.

Disclaimer

This press release is provided for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Regenerative medicine and longevity therapies encompass evolving areas of clinical research, and any specific procedures, cellular signaling techniques, or products referenced have not been evaluated, approved, or cleared by the U.S. Food and Drug Administration (FDA) unless explicitly stated. The information, opinions, and statements contained herein — including descriptions of physician training, clinical partnerships, and educational programs — are intended solely to detail corporate developments and industry initiatives. They should not be interpreted as guarantees of safety, efficacy, or specific medical outcomes, nor do they replace direct clinical evaluation by a qualified healthcare professional. Individual patient suitability for regenerative therapies varies, and healthcare decisions should always be made in consultation with a licensed medical practitioner. Furthermore, forward-looking statements regarding future programs, partnerships, or industry shifts reflect current company expectations and involve risks and uncertainties that could cause actual outcomes to differ materially.

Media Contact

sanjiv@regentherapy.com